Exicure (XCUR): Prakiraan rega marang bathi
The startup format and reliance on stock options create personnel risks, as confirmed by the expected P/E valuation of Exicure, Inc. (XCUR), where 0.00 represents the current metric level. Business stability is based on the unique SNA platform for rare pathologies. A restructuring of the R&D pipeline focused on targeted therapy will end the current lull and help balance the asset's market value.
Rincian metrik keuangan lan pasar Exicure Corp (XCUR)
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Exicure, Inc.|XCUR - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Exicure, Inc.|XCUR - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Exicure Inc.|XCUR - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Exicure|Indikator likuiditas cepet exicuretx.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
XCUR - Asil keuangan resik|Bathi mangsa ngarep Exicure, Inc.|XCUR - Pangali rega marang bathi|Pangali Forward P/E Exicure, Inc.|XCUR - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Exicure Inc.|XCUR - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Exicure|XCUR - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan exicuretx.com|XCUR - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Exicure, Inc.
- informasi babagan volume dodolan lan pendapatan:
Analisis dhasar perusahaan:XCUR Exicure
Exicure, Inc. focuses on developing nucleic acid therapies without stable revenues, relying instead on external financing and grants. Under these conditions, the company's future P/E trajectory reflects market expectations for future earnings, allowing for an assessment of investment risk through the ratio of current market capitalization to projected cash flows, which determines the fundamental stability of the business on this chart.
Karo sapa Exicure, Inc. saingan
Pangali Forward P/E TEM|Prakiraan rega marang bathi Qiagen NV QGEN|Ionis Pharma - Prakiraan rega marang bathi|Pangali Forward P/E Repligen Inc. RGEN|RNA - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi CRSP (crisprtx.com)|WGS: Pangali Forward P/E|Rasio prakiraan rega marang bathi Ultragenyx Pharmaceutical Inc. (RARE)|Prakiraan rega marang bathi BEAM|SRPT: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E TWST|Kapitalisasi marang proyeksi bathi 10xgenomics.com|Rega marang bathi mangsa ngarep Intellia Therapeutics, Inc. NTLA|STOK: Rasio rega marang bathi mangsa ngarep|BioLife Corp - Pangali Forward P/E|Wave Pharma (WVE) - Prakiraan rega marang bathi|MAZE (Maze Therapeutics Inc) - Prakiraan rega marang bathi|SION - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi PRME|Rasio rega marang bathi mangsa ngarep TSHA (Taysha Gene Therapies Inc)|Pangali Forward P/E QURE|Prakiraan rega marang bathi MeiraGTx Corp MGTX|REGENXBIO Inc. - Prakiraan rega marang bathi|Pangali Forward P/E solidbio.com SLDB|OCGN - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi PACB (Pacific Biosciences of California, Inc.)|BNTC: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep DSGN|Rega marang bathi mangsa ngarep Rocket Pharmaceuticals|Rasio rega marang bathi mangsa ngarep FDMT (4dmoleculartherapeutics.com)|Pangali Forward P/E LXEO|Pangali Forward P/E korrobio.com (KRRO)|Pangali Forward P/E EDIT (Editas)|Silence Therapeutics Corp (SLN) - Rasio prakiraan rega marang bathi|PRQR: Prakiraan rega marang bathi|CDXS (Codexis, Inc.) - Rasio rega marang bathi mangsa ngarep|SGMO: Pangali Forward P/E|NAUT - Kapitalisasi marang proyeksi bathi|MGX (Metagenomi, Inc) - Pangali Forward P/E|Prakiraan rega marang bathi Precision BioSciences Inc. (DTIL)|Prakiraan rega marang bathi GBIO (Generation Bio Co.)|Pangali Forward P/E boundlessbio.com (BOLD)|Rega marang bathi mangsa ngarep Imunon IMNN|Pangali mangsa ngarep rega marang bathi PHIO|Mustang Bio Corp - Pangali Forward P/E|Rasio prakiraan rega marang bathi TransCode Therapeutics|BNGO (bionanogenomics.com) - Prakiraan rega marang bathi|adnas.com - Pangali mangsa ngarep rega marang bathi|BLUE (bluebird bio) - Pangali Forward P/E|ImmunoPrecise (IPA) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Omega (OMGA)|Singular Genomics Corp - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E RGLS (Regulus Therapeutics)|SYRS - Prakiraan rega marang bathi|TBIO: Prakiraan rega marang bathi|Kapitalisasi marang proyeksi bathi TRACON Pharmaceuticals Inc. TCON|UBX (Unity Bio) - Prakiraan rega marang bathi
